MaaT Pharma: sufficient cash until Q3 2023











Photo credit © Maat Pharma


(Boursier.com) — The total turnover of MaaT Pharma for the 1st half of 2022 amounts to 0.5 million euros, (0.4 ME for the 1st half of 2021. In 2021, the turnover was invoiced from February 2021 while in 2022, the company benefits from 6 full months of turnover.

As of June 30, 2022, total cash and cash equivalents amounted to €38.4 million (€41.1 million as of March 31, 2022 and €43.3 million as of December 31, 2021). The net change in cash over the 1st half of 2022 is €4.9 million. This change includes €2.7 million in new bank loans with BNP Paribas and Caisse d’Epargne Rhône Alpes (CERA) received during the second quarter of 2022. Additional drawings of €4.4 million on existing loans signed between CIC and Bpifrance are expected by the end of 2022.

The company estimates that it has sufficient cash to cover the needs of development programs until the end of the third quarter of 2023.

“The 2nd quarter was marked by new advancements in our pipeline, in particular with a crucial milestone reached for MaaT Pharma. The announcement of results indicating a satisfactory safety profile and good colonization (“engraftment”) for MaaT033, our 2nd drug candidate, opens up attractive market opportunities to extend our development to a wider patient population since we are focusing on the prevention of complications in patients receiving allo-CSH2 but also for all hematological malignancies.” said Hervé Affagard, CEO and co-founder of MaaT Pharma.


©2022 Boursier.com






Source link -87